Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: Modified precipitation procedure and HPLC compared

Clinical Chemistry

Volumn 44, Issue 6, 1998, Pages 1269-1274

  Schütz, Ekkehard ^a   Shipkova, Maria ^a   Niedmann, Paul Dieter ^a   Wieland, Eberhard ^a   Armstrong, Victor William ^a   Oellerich, Michael ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEETHYLLIDOCAINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERBILIRUBINEMIA;

EID: 0031747946     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.6.1269     Document Type: Article

References (23)

1. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by human liver cytochrome P450IIIA4. Clin Pharmacol Ther 1989;46:521-7.
2. Oellerich M, Raude E, Burdelski M, Schulz M, Schmidt FW, Ringe B, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987;25:845-53.
3. Schiffman ML, Fisher RA, Sanyal AJ, Edinboro LE, Luketic VA, Purdum III PP, et al. Hepatic lidocaine metabolism and complications of cirrhosis. Transplantation 1993;55:830-4.
4. Arrigoni A, Gindro T, Aimo G, Capello N, Meloni A, Benedetti P, et al. Monoethylglycinexylidide test: a prognostic indicator of survival in cirrhosis. Hepatology 1994;20:383-7.
5. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140-7.
6. Oellerich M, Burdelski M, Lautz HU, Schulz M, Schmidt FW, Herrmann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990;12:219-26.
7. Oellerich M, Burdelski M, Lautz HU, Binder L, Pichlmayr R. Predictors of one-year pretransplant survival in patients with cirrhosis. Hepatology 1991;14:1029-34.
8. Burdelski M, Schütz E, Nolte-Buchholtz S, Armstrong VW, Oellerich M. Prognostic value of the MEGX-test in pediatric liver transplant candidates. Ther Drug Monit 1996;18:378-82.
9. Schütz E, Luy-Kaltefleiter M, Kaltefleiter M, Armstrong VW, Burdelski M, Ringe B, Oellerich M. The value of serial determination of MEGX and hyaluronic acid after orthotopic liver transplantation. Eur J Clin Invest 1996;26:907-16.
10. Burdelski M, Oellerich M, Düwel J, Raith H, Scheruhn M, Ringe B, et al. Pre-and post-transplant assessment of liver function in paediatric liver transplantation. Eur J Pediatr 1992;151(Suppl 1):39-43.
11. Potter J, Oellerich M. The use of lidocaine as a test of liver function in liver transplantation. Liver Transplant Surg 1996;2: 211-24.
12. Lehmann U, Armstrong VW, Schütz E, Regel G, Pape D, Oellerich M. Monoethylglycinexylidide as an early predictor of posttraumatic multiple organ failure. Ther Drug Monit 1995;17:125-32.
13. Schröter J, Wandel C, Böhrer H, Schmidt H, Böttiger BW, Martin E. Lignocaine metabolite formation: an indicator for liver dysfunction and predictor of survival in surgical intensive care patients. Anaesthesia 1995;50:850-4.
14. Zoppi F, Fumagalli C. Improved measurement of MEGX in serum with the Abbott TDx [Letter]. Clin Chem 1992;38:441-2.
15. Andreeva M, Niedmann PD, Schütz E, Wieland E, Armstrong VW, Oellerich M. MEGX determination by use of HPLC with fluorescence determination [Technical Brief]. Clin Chem 1997;43: 1081-3.
16. Passing H, Bablok W. A new biomedical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison in clinical chemistry. J Clin Chem Clin Biochem 1983;21: 709-20.
17. Kaiser H. Zum Problem der Nachweisgrenze. Z Anal Chem 1965; 209:1-18.
18. Oellerich M, Ringe B, Gubernatis G, Pilchmayr R, Burdelski M, Lamesch P, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989;i:640-2.
19. Schneider MC, Rayburn BK, Frey R. Interference by intravenous fluorescein with drug assays in the Abbott TDx [Letter]. Clin Chem 1983;29:2001.
20. Berne CA, Zubey LA, Demers LM. Interference of serum mercury with the Abbott TDx [Letter]. Clin Chem 1991;37:1659.
21. Valdes R Jr. Endogenous digoxin-like immunoreactive factors: impact on digoxin measurements and potential physiological implications. Clin Chem 1985;31:1525-32.
22. Datta P, Xu L, Malik S, Landicho D, Ferreri L, Halverson K, et al. Effect of antibody specificity on results of selected digoxin immunoassays among various clinical groups. Clin Chem 1996;42: 373-9.
23. Shaikh IM, Lau BW, Siegfried BA, Valdes R Jr. Isolation of digoxin-like immunoreactive factors from mammalian adrenal cortex. J Biol Chem 1991;266:13672-8.